Kornimate/medical-research-clean huggingface dataset:
g-csf in stimulating peripheral stem cells for autologous stem cell transplant in treating patients with chronic phase chronic myeloid leukemia in complete remission

Conditions: Leukemia

Summary: rationale: giving colony-stimulating factors, such as g-csf, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant. purpose: this phase i trial is studying the side effects of g-csf in stimulating peripheral stem cells for autologous stem cell transplant in treating patients with chronic phase chronic myeloid leukemia in remission.

objectives: * determine the feasibility and safety of harvesting adequate numbers of cd34-positive peripheral blood stem cells using filgrastim (g-csf) in patients with chronic phase chronic myeloid leukemia in complete cytogenetic remission. * determine the safety of temporarily discontinuing treatment with imatinib mesylate and using g-csf during the harvesting procedure, in terms of the percentage of philadelphia chromosome (ph)-positive cells before and after stem cell harvest, in these patients. outline: patients receive filgrastim (g-csf) and then undergo apheresis for up to 5 days. after completion of apheresis, patients resume treatment with imatinib mesylate off study. patients may later undergo autologous peripheral blood stem cell transplantation, when deemed necessary. projected accrual: a total of 20 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * diagnosis of chronic phase chronic myeloid leukemia * in complete cytogenetic remission, confirmed by bone marrow biopsy within the past month * has been receiving imatinib mesylate for ≥ 3 months\* note: \*imatinib mesylate is held during the study harvesting procedure * no myelofibrosis on bone marrow ≥ 3+ * ineligible for or refused allogeneic stem cell transplantation patient characteristics: age * over 18 performance status * ecog 0-1 life expectancy * not specified hematopoietic * wbc \> 3,000/mm\^3 * platelet count \> 100,000/mm\^3 hepatic * adequate hepatic function for stem cell transplantation renal * adequate renal function for stem cell transplantation cardiovascular * adequate cardiovascular function for stem cell transplantation pulmonary * adequate pulmonary function for stem cell transplantation other * hiv negative prior concurrent therapy: biologic therapy * no other concurrent biologic therapy chemotherapy * more than 4 weeks since prior chemotherapy * no other concurrent chemotherapy endocrine therapy * not specified radiotherapy * no concurrent radiotherapy surgery * no concurrent surgery other * no other concurrent experimental therapy

Keywords: chronic phase chronic myelogenous leukemia
a study of mk0476 in the treatment of asthma patients aged 2-5 years (0476-907)

Conditions: Asthma

Summary: a study to determine the efficacy of mk0476 in the treatment of asthmatic patients aged 2 to 5 years.


Eligibility criteria:
inclusion criteria: * male or female between and including the ages of 2 and 5 years * patient was treated with steroids for an asthma episode in the last 3 months * patient was admitted to the hospital or emergency room in the last 3 months * patient is able to chew a tablet exclusion criteria: * patient has been in a research study in the past 4 weeks * patient has visited the emergency room for an asthma episode in the past week * patients has a history of stomach, heart, liver, nerve, kidney or blood disease
efficacy of modified constraint-induced movement therapy on the upper limb function of sub-acute stroke patients in peshawar pakistan

Conditions: Stroke

Summary: this rct will also help the clinicians to provide the best treatment to their patients for better outcomes. the objective of the study is to determine the efficacy of modified constraint-induced movement therapy on the upper limb function of sub-acute stroke patients in peshawar pakistan. alternative hypothesis: there will be a difference in the means of modified constraint-induced movement therapyand traditional physical therapy on the upper limb function of subacute stroke patients.


Eligibility criteria:
inclusion criteria: * 1. age 30 to 60 years * 2. both female \& male will be included. * 3. cognitive and lingual ability to communicate with the research staff. * 4. a minimum of 10 degrees of active finger extension and 20 degrees of active wrist extension(16). * 5. a history of a single stroke resulting in a hemiparesis exclusion criteria: * 1. recurrent stroke during the training period. * 2. neurological or orthopedic disorders prohibiting the use of the paretic arm. * 3. patients who doesn't show willingness to participate in the study.
effect of research participation versus usual clinical treatment on pain in patients with musculoskeletal disorders

Conditions: Musculoskeletal Diseases; Osteoarthritis, Knee; Illness Perceptions

Summary: this study explores the effects on pain, function and illness perceptions, of participating in clinical research versus being treated with standard care in patients with musculoskeletal disorders.

musculoskeletal (msk) disorders are a major burden on individuals, health systems, and social care systems. increases in life expectancy and ageing populations are expected to make msk disorders one of the leading causes of disability by the year 2020. when faced with a potentially life changing diagnosis of a chronic disease, people (in general) develop an organized pattern of perceptions about their condition, and how it impacts their lives and often, the essentially same stressful event may cause significant variations in perceptions. these different perceptions and coping strategies might affect the way the individual chooses to handle the disease and seek health care assistance, which altogether eventually may affect the course of the illness. study participation besides reassurance, could be hypothesized to induce beneficial outcomes for the patients, but is it reasonable to expect an effect of study participation regardless of study intervention, design and group allocation? and is an eventual effect mainly derived from the intervention or from the participants being a selected group? it remains to be clarified, whether and how study participation affects the individual's treatment effect and perceptions of the illness.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * diagnosed with a musculoskeletal disorder * currently enrolled in a health research study hosted by the outpatient osteoarthritis clinic at frederiksberg hospital or being treated in the outpatient osteoarthritis clinic at frederiksberg hospital and not participating in a health research study * reads and speaks danish * consents to participation in this survey exclusion criteria: • we have no formal exclusion criteria

Keywords: musculoskeletal diseases osteoarthritis, knee cohort study illness perceptions
ziprasidone and sertraline in ptsd

Conditions: Post-traumatic Stress Disorder

Summary: serotonin re-uptake inhibitors, such as sertraline, are the medication of choice in post-traumatic stress disorder. however, it takes several weeks before they ameliorate symptoms. therefore, we will add ziprasidone (vs. placebo) medication during the first four weeks of sertraline in order to find out if this strategy accelerates symptomatic relief.

a current problem in the pharmacotherapy of ptsd is that the medication of choice, serotonin re-uptake inhibitors, take several weeks before they show considerable effects on ptsd symptoms. addition of typical neuroleptics, such as ziprasidone, offers a potential strategy to bring about a faster symptomatic relief, because they display anxiolytic properties without the risk of dependence. therefore, in addition to standard sertraline therapy (at least 8 weeks), we will give ziprasidone vs. placebo over the first four weeks in a double-blind randomized design.

Eligibility criteria:
inclusion criteria: clinical diagnosis of post-traumatic stress disorder exclusion criteria: lifetime psychotic disorders, current substance dependency, gravidity, lactation, tartrazine hypersensitivity, contraindication against sertraline or ziprasidone

Keywords: ziprasidone, sertraline, ptsd
efficacy of social cognition training in schizophrenia

Conditions: Schizophrenia

Summary: the term social cognition refers to how social information is processed. individuals with schizophrenia and schizoaffective disorder have been shown to have significant deficits in social cognition. moreover, it has been speculated that these deficits may in turn have a negative impact on their overall functioning. behavioral interventions targeting social cognition are just beginning to emerge, and there is a need to evaluate their efficacy. objectives: this is a small trial evaluating the efficacy of social cognition interaction training (scit) an experimental behavioral treatment for improving social cognition in schizophrenia. research design and methodology: approximately 48 participants with schizophrenia-spectrum disorders will be randomized into one of two conditions: 1) a 20 to 24 session manualized social cognition interaction training group (scit), or 2) wait-list control. pre-and post-group therapy assessments of symptoms, social cognition, basic cognition, and community function will be conducted. data obtained from this study will allow us to determine the efficacy of scit training in improving symptom, cognitive, and functional measures.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * age between 18 and 65 * minimum of 30 days since discharge from last hospitalization * minimum of 30 days since last change in psychiatric medications * no housing changes in the past 30 days exclusion criteria: * current diagnosis of alcohol or substance abuse/dependence * history of brain trauma or neurological disease * mental retardation or developmental disability * auditory or visual impairment that would interfere with study procedures

Keywords: schizophrenia social cognition cognition treatment outcome
fertility awareness in university students

Conditions: Educational Video

Summary: recent evidence showed that undergraduate students have inappropriate knowledge about reproductive health and infertility. the investigators' aim was to assess the effectiveness of a brief intervention (video) in increasing the knowledge regarding fertility issues, fertility risk factors and infertility definition.


Eligibility criteria:
inclusion criteria: * undergraduate student exclusion criteria: * having knowledge of a fertility problem

Keywords: infertility fertility awareness health interventions young adults
conversion surgery in stage iv or unresectable gastric cancer

Conditions: Stage IV or Unresectable Gastric Cancer

Summary: this study aims to identify the safety and the survival benefit of the conversion surgery in stage iv or unresectable gastric cancer. the study designed single-arm phase ii trial. all the patients would undergo curative-intent radical gastrectomy after palliative chemotherapy if the tumor responded to the chemotherapy. primary endpoint was three-year overall survival. secondary endpoints included short-term postoperative outcomes within 30 days, three-year relapse free survival, and success rate of conversion surgery (rate of r0 resection).

the survival rate of patients with stage iv gastric cancer (gc) is very low. recently, several retrospective studies about conversion surgery have been introduced. the results of the studies showed around 30\~40% of three-year survival rate in conversion surgery group. eight institutions in catholic university of korea analyzed 419 stage iv gc patients, and they had divided into four groups: chemotherapy only, chemotherapy followed by gastrectomy, gastrectomy followed by chemotherapy, and best supportive care group. the group of gastrectomy followed by chemotherapy, which is similar with conversion surgery, showed 40% of three-year survival rate. however, the study included only small number of patients who were in conversion surgery group, and had several biases. thus, we planned multi-national, multi-center phase ii trial for conversion surgery in stage iv or unresectable gc.

Eligibility criteria:
inclusion criteria: * gastric adenocarcinoma * stage iv or unresectable gastric cancer was diagnosed by pre-operative evaluation including endoscopy, endoscopic ultrasound, computed tomography (ct), positron emission tomography-computed tomography (pet ct), or staging laparoscopy * partial or complete response to chemotherapy * eastern cooperative oncology group (ecog) score \<3 * who agreed to enroll the study exclusion criteria: * synchronous or metachronous malignancy * remnant gastric cancer * bmi less than 18.5 * pregnancy
non-invasive placental chromosome exploration of intrauterine growth restriction

Conditions: Fetal Growth Retardation

Summary: the objective of this project is the non-invasive prenatal detection of placenta-limited aneuploidies, in patients whose fetuses have a intrauterine growth restriction below 3rd percentile, in parallel with an amniocentesis. this study will allow the chromosomal study of the placenta in pregnant women whose genetic prenatal diagnosis, made by amniocentesis, does not allow exploring the placental causes of fetal rciu.

placental chromosomal aneuploidies will be detected by high-throughput whole genome sequencing of non-cellular dna present in maternal plasma during pregnancy. the study of the cfdna will be carried out from a blood sample with the automated solution veriseq nipt (illumina) using the software illumina veriseq v2, allowing the detection of all chromosomal abnormalities.

Eligibility criteria:
inclusion criteria: * over 18 years old, * treated in the ddiane fetal medicine centre at the bordeaux university hospital, * having a fetus with iugr diagnosis below the 3rd percentile (after reference medical ultrasound), * from 16 weeks of amenorrhea or more, * accepting an invasive prenatal diagnosis by amniocentesis with array comparative genomic hybridization exclusion criteria: childbearing women who: * do not accept a non-invasive prenatal diagnosis (amniocentesis) * have a fetus with non-isolated iugr (associated with other ultrasound signs) * do not consent to participate in the research protocol

Keywords: non invasive prenatal testing cell- free dna trisomy placenta confined mosaic
asthma control and clinical practice in hungary 2009

Conditions: Asthma Control Level

Summary: a prospective study led amongst pulmonologists. patients asthma control level will be evaluated based on gina guideline criteria. hrqol measured by visual analogue scale. clinical practice: non controlled patients therapy assessed.


Eligibility criteria:
inclusion criteria: * asthma patients treated with ics or bronchodilators exclusion criteria: * copd * pulmonary cancer * pulmonary tuberculosis

Keywords: asthma control level visual analogue scale
evaluation of caregiver burden and depression severity in patients with hemiplegia

Conditions: Hemiplegia; Caregiver Burden; Depression

Summary: this study aimed to evaluate the caregiving burden and severity of depression in patients with right hemiplegia and left hemiplegia.

stroke is a disease characterized by neurological symptoms and signs lasting more than 24 hours, which can lead to death after the interruption of brain blood flow or due to focal brain damage. post-stroke disability affects the patient's quality of life, makes the patient dependent on the caregiver, creates a caregiver burden, and brings socioeconomic and social consequences. different hemispheres of the brain undertake different tasks. different clinical conditions may occur in stroke patients with right or left hemiplegia following cerebrovascular infarction. this may affect the care burden of caregivers and the severity of depression. it was thought that knowing the care burden of patients with right and left hemiplegia would positively contribute to the quality of care given to patients.this study aimed to evaluate the caregiving burden and severity of depression in patients with right hemiplegia and left hemiplegia.

Eligibility criteria:
inclusion criteria: * hemiplegia patients between the ages of 18 and 75 were included. * caregivers over 18 years of age * at least 3 months must have passed since the patient was diagnosed. * caregivers of patients should be their first and second degree relatives. * caregivers must be competent to understand what they read and complete the questionnaires. * caregivers must have been caring for their patients for at least 3 months. exclusion criteria: * patients and caregivers with a history of psychiatric illness
family centered (face) advance care planning for teens with cancer

Conditions: Cancer

Summary: advance care planning (acp) prepares patients and their loved ones for future health care decisions, including end-of-life decisions. yet, the needs of adolescent oncology patients for participation in acp, despite its priority, is not well studied. our goal is to test a model of acp that anticipates these issues, fully empowers the family and adolescent, and keeps the key role of health care professionals central, building on our earlier work. we hypothesized family centered (face) acp, would: (1) increase congruence in treatment preferences between adolescents and surrogates; (2) decrease decisional conflict for adolescents; and (3) increase quality of communication compared with controls.

condition the purpose of the face intervention is to facilitate conversations about eol care between adolescents and their legal guardians or surrogates in order to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. this intervention will consist of three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. each session will be followed by a 15 minute assessment, using process measures to assess participants' ratings of the quality of the communication with the facilitator and satisfaction (negative and positive emotions in response to session) on a likert scale. a research assistant, not the facilitator, will conduct the immediate post evaluation sessions. a standard of care comparison condition will also be assessed and measures administered at the same time intervals: at baseline, one week intervals for three weeks for process measures and statement of treatment preferences, and at 3 month-post intervention follow-up.

Eligibility criteria:
inclusion criteria: * age ≥14.0 years and \<21.0 years for adolescents at enrollment; * age ≥ 21.0 years for surrogates at enrollment; * iq \> 70 or not known to be developmentally delayed; * depression score on beck depression inventory, second edition (bdi-ii) total score \< 26; * primary language english exclusion criteria: * in foster care; * developmentally delayed; * suicidal or homicidal or psychotic at time of screening; * not understand or speak english; and * failure on mini mental status exam

Keywords: advance care planning, palliative care, pediatric
a survey on the role and benefits of online social networks on filipino patients with psoriasis

Conditions: Psoriasis

Summary: with the rise of usage of the internet, online social networks have recently been gaining popularity. joining these groups can be beneficial to patients with chronic medical illness, such as psoriasis.this was a cross-sectional online survey of psoriasis patients in the philippines who are members of online support groups. the survey was conducted for a period of three months.the purpose of the research project was to describe the demographics, disease characteristics, activities and benefits of online support groups to filipino patients with psoriasis. the extent to which members experience empowering processes and outcomes was also evaluated.


Eligibility criteria:
inclusion criteria: * diagnosis of psoriasis * individuals who are willing to complete the online survey * proficiency in english * membership in an online psoriasis support network exclusion criteria: * nonmembers * unwilling to participate in the study

Keywords: online social network psoriasis filipino
teplizumab for prevention of type 1 diabetes in relatives "at-risk"

Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance

Summary: the study will determine whether the anti-cd3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (t1d) in relatives determined to be at very high risk for developing the disease. teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. the results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. the purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.

the study plans to enroll approximately 71 subjects between the ages of 8-45 years, over 2-3 years. the study is projected to last between 4-6 years, depending upon rate of enrollment and number of subjects who develop diabetes. the main study objective is to determine whether intervention with teplizumab will prevent or delay the development of type 1 diabetes in high risk autoantibody positive non-diabetic relatives of individuals with t1d. secondary outcomes are to include analyses of c-peptide and other measures from oral glucose tolerance testing (ogtt), safety, tolerability, and other mechanistic outcomes will be assessed during the study.

Eligibility criteria:
inclusion criteria: * between ages of 8-45 years * have a relative with type 1 diabetes * if first degree relative must be 8-45 years old (brother, sister, parent, offspring) * if second degree relative must be between 8-20 years old (niece, nephew, aunt, uncle, grandchild, cousin) * abnormal glucose tolerance by ogtt confirmed with 7 weeks of baseline visit \[fasting blood glucose greater than 110mg/dl or and less than 126 mg/dl or 2 hour glucose greater or equal to 140 mg/dl and less than 200 mg/dl or 30, 60, or 90 minute value on ogtt greater than or equal to 200 mg/dl\] * presence of at least two confirmed diabetes autoantibodies exclusion criteria: * type 1 diabetes previously diagnosed or detected at screening \[fasting glucose greater or equal to 126 mg/dl or 2 hour glucose greater or equal to 200 mg/dl\] * abnormalities in blood counts, liver enzymes, international normalised ratio (inr), * positive purified protein derivative (ppd) test * vaccination with live virus within 6 weeks of randomization * evidence of acute infection based on laboratory testing or clinical evidence * serological evidence of past current or past hiv , hepatitis b, or hepatitis c infection * be currently pregnant or lactating * prior treatment with study drug * prior treatment with other monoclonal antibody in past one year

Keywords: type 1 diabetes pre-diabetic autoantibody positive at risk for type 1 diabetes glucose intolerance relatives of people with type 1 diabetes